Epsilon M&A Deal Report - GES Group

Transaction Multiples for the Valuation of Private Companies

Altan Pharma > GES Group

Announced Date : 11 June 2015

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Altan Pharma

Target GES Group

Target Country Spain

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> The GES Group develops, manufactures and markets specialty injectable drugs for the hospital and healthcare provider market.

> GES, headquartered in Spain, is comprised of 3 operating ...

No EMAT :

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating **

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1224

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
16/06/2015	Private Group led by HLD, UI Gestion and DV France	IP Santé Domicile (IPS)	France	0
10/12/2012	Eczacıbaşı-Monrol Nükleer Ürünler San. ve Tic. A.S	Capintec	United States	0

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database